ASPRV1

Across TCGA cell cohorts, ASPRV1 mutation is significantly associated with the drug of many other genes, with 11 significant associations in total. BLOOD_Leukemia shows the largest number of these associations.

The most reproducible ASPRV1-associated genes across cancer lineages are Refametinib, PD0325901, and Trametinib. Each is linked with ASPRV1 in more than 1 cancer types. Because this analysis shows association rather than direction, both ASPRV1-to-partner and partner-to-ASPRV1 results are reported.

Each partner links to its own Q-omics profile. The box plot shows the strongest example, Refametinib grouped by ASPRV1-low versus ASPRV1-high in BLOOD_Leukemia.

mutation associated genes by consensus

Ranked by combined sampling and lineage consensus. X-score (ASPRV1→partner) and Y-score (partner→ASPRV1) are standardized regression coefficients; both directions are reported because the association is undirected. p-values are from the association test.

Lineage	Partner gene	X-score	Y-score	p(X)	p(Y)	Sampling consensus	Lineage consensus
BLOOD_Leukemia	Refametinib →	-0.749	-3.000	.025	.028	3	1
BLOOD_Leukemia	PD0325901 →	-0.875	-2.893	.019	.030	3	1
BLOOD_Leukemia	Trametinib →	-0.798	-3.000	.046	.028	3	1
BLOOD_Leukemia	Ara-G →	+0.707	+3.038	.008	.013	3	1
BLOOD_Leukemia	RU-SKI 43 →	+0.304	+3.038	.029	.013	3	1
BLOOD_Leukemia	SCH772984 →	-0.617	-2.964	.022	.029	2	1

Each partner links to its Q-omics profile. Showing the 6 strongest of 11 associations by consensus.

Refametinib by ASPRV1 expression — BLOOD_Leukemia

Explore this box plot interactively →